CC-292,
N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,
AVL-292,
1202757-89-8,
spebrutinib,
cc-292,
UNII-DRU6NG543J,
DRU6NG543J,
AVL292,
AVL 292,
N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide,
CC-292 (AVL-292),
AK198940,
N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide,
N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide,
n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,
Btk inhibitor CC-292,
Spebrutinib [USAN:INN],
Spebrutinib (USAN/INN),
SCHEMBL626216,
GTPL7837,
CHEMBL3301625,
EX-A255,
KXBDTLQSDKGAEB-UHFFFAOYSA-N,
HMS3653E15,
AOB87153,
BCP07702,
KS-000005TU,
CC-292,LMK-435,
2235AH,
ABP001105,
AVL-292, CC-292,
BDBM50161162,
CC 292,
MFCD25976876,
s7173,
ZINC72319585,
AKOS026670200,
AKOS032949981,
Spebrutinib (CC-292, AVL-292),
CS-1482,
DB11764,
SB14609,
NCGC00386306-06,
AS-16998,
BC600508,
HY-18012,
QC-11653,
SC-94180,
AB0165821,
FT-0751022,
SW219474-1,
A13202,
D10730,
W-6114,
N-(3-((5-fluoro-2-((4-(2-methoxyethoxyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide,
N-(3-{5-fluoro-2-[4-(2-methoxy-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-phenyl)-acrylamide,
N-{3-[(5-FLUORO-2-{[4-(2-METHOXYETHOXY)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}PROP-2-ENAMIDE,
C22H22FN5O3,
LMK-235,
ACN-025786,
A3206,
2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-,
2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-,
N-(3-(2-(4-(2-methoxyethoxy)phenylamino)-5-fluoropyrimidin-4-ylamino)phenyl)acrylamide,